Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression.
Bladder cancer
Mutation
miRNA
miRNA-mRNA network
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
29 Oct 2019
29 Oct 2019
Historique:
received:
30
04
2019
accepted:
02
09
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
25
3
2020
Statut:
epublish
Résumé
Bladder cancer (BC) is a common urothelial malignancy, characterized by a high recurrence rate. The biology of bladder cancer is complex and needs to be deciphered. The latest evidence reveals the critical role of the non-coding RNAs, particularly microRNAs (miRNAs), as vital regulatory elements in cancer. We performed a miRNAs microarray using paired tissues (tumor and adjacent normal bladder tissue), followed by the validation with qRT-PCR of five selected transcripts. Additional next-generation sequencing investigation established the interconnection among the altered miRNAs and mutated genes. Based on the overlapping between TCGA data and data obtained in the study, we focused on the systematic identification of altered miRNAs and genes mutated involved in bladder cancer tumorigenesis and progression. By overlapping the miRNAs expression data, the two patient cohorts, we identified 18 miRNAs downregulated and, 187 miRNAs upregulated. qRT-PCR validation was completed using a selected panel of two downregulated (miR-139-5p and miR-143-5p) and three up-regulated miRNAs (miR-141b, miR-200 s or miR-205). Altered miRNAs patterns are interrelated to bladder tumorigenesis, allowing them to be used for the development of novel diagnostic and prognostic biomarkers. Three EMT-related upregulated miRNAs have an essential role in the molecular mechanisms, specifically key processes underlying tumorigenesis, invasion and metastasis. Using the Ampliseq Cancer Panel kit and Ion Torrent PGM Next-Generation Sequencing an increased mutation rate for TP53, FGFR3, KDR, PIK3CA and ATM were observed, but the mutational status for only TP53 was correlated to the survival rate. The miRNAs pattern, along with the gene mutation pattern attained, can assist for better patient diagnosis. This study thereby incorporates miRNAs as critical players in bladder cancer prognosis, where their altered gene expression profiles have a critical biological function in relationship with tumor molecular phenotype. The miRNA-mRNA regulatory networks identified in BC are ripe for exploitation as biomarkers or targeted therapeutic strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer (BC) is a common urothelial malignancy, characterized by a high recurrence rate. The biology of bladder cancer is complex and needs to be deciphered. The latest evidence reveals the critical role of the non-coding RNAs, particularly microRNAs (miRNAs), as vital regulatory elements in cancer.
METHOD
METHODS
We performed a miRNAs microarray using paired tissues (tumor and adjacent normal bladder tissue), followed by the validation with qRT-PCR of five selected transcripts. Additional next-generation sequencing investigation established the interconnection among the altered miRNAs and mutated genes. Based on the overlapping between TCGA data and data obtained in the study, we focused on the systematic identification of altered miRNAs and genes mutated involved in bladder cancer tumorigenesis and progression.
RESULTS
RESULTS
By overlapping the miRNAs expression data, the two patient cohorts, we identified 18 miRNAs downregulated and, 187 miRNAs upregulated. qRT-PCR validation was completed using a selected panel of two downregulated (miR-139-5p and miR-143-5p) and three up-regulated miRNAs (miR-141b, miR-200 s or miR-205). Altered miRNAs patterns are interrelated to bladder tumorigenesis, allowing them to be used for the development of novel diagnostic and prognostic biomarkers. Three EMT-related upregulated miRNAs have an essential role in the molecular mechanisms, specifically key processes underlying tumorigenesis, invasion and metastasis. Using the Ampliseq Cancer Panel kit and Ion Torrent PGM Next-Generation Sequencing an increased mutation rate for TP53, FGFR3, KDR, PIK3CA and ATM were observed, but the mutational status for only TP53 was correlated to the survival rate. The miRNAs pattern, along with the gene mutation pattern attained, can assist for better patient diagnosis.
CONCLUSION
CONCLUSIONS
This study thereby incorporates miRNAs as critical players in bladder cancer prognosis, where their altered gene expression profiles have a critical biological function in relationship with tumor molecular phenotype. The miRNA-mRNA regulatory networks identified in BC are ripe for exploitation as biomarkers or targeted therapeutic strategies.
Identifiants
pubmed: 31665050
doi: 10.1186/s13046-019-1406-6
pii: 10.1186/s13046-019-1406-6
pmc: PMC6819535
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
433Subventions
Organisme : UEFISCDI
ID : PNCDI III 2015-2020
Organisme : UEFISCDI
ID : PN-II-PT-PCCA-2011-3.1-1221
Références
J Hum Genet. 2017 Jan;62(1):49-56
pubmed: 27357429
Future Oncol. 2016 Oct;12(19):2243-63
pubmed: 27381494
Int J Nanomedicine. 2015 Jan 20;10:791-800
pubmed: 25653521
Cell Physiol Biochem. 2016;39(2):453-66
pubmed: 27383203
J Biol Chem. 2013 Feb 1;288(5):3275-88
pubmed: 23239884
Biomed Res Int. 2016;2016:7618342
pubmed: 27807540
Int J Cancer. 2009 Jul 15;125(2):345-52
pubmed: 19378336
Cancer Biol Ther. 2014 Sep;15(9):1239-47
pubmed: 24971884
Med Sci (Basel). 2018 Dec 07;6(4):null
pubmed: 30544619
Eur Urol. 2011 May;59(5):671-81
pubmed: 21296484
Cancer Med. 2016 Aug;5(8):1856-62
pubmed: 27292588
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Oncotarget. 2015 Nov 10;6(35):37335-48
pubmed: 26484567
Clin Cancer Res. 2009 Aug 15;15(16):5060-72
pubmed: 19671845
Urol Oncol. 2007 Sep-Oct;25(5):387-92
pubmed: 17826655
J Urol. 2012 Aug;188(2):615-23
pubmed: 22704449
Onco Targets Ther. 2016 Jun 02;9:3369-80
pubmed: 27330317
Pathol Oncol Res. 2018 Apr;24(2):407-417
pubmed: 28577130
Curr Drug Targets. 2015;16(2):115-24
pubmed: 25654736
PLoS One. 2015 Jan 28;10(1):e0117284
pubmed: 25629698
Am J Pathol. 2013 Apr;182(4):1171-9
pubmed: 23410519
EXCLI J. 2018 Jan 02;17:3-13
pubmed: 29383014
Curr Med Chem. 2013;20(29):3561-73
pubmed: 23834177
J Cell Biochem. 2017 Jan;118(1):7-14
pubmed: 27216701
Biochim Biophys Acta Gen Subj. 2017 Jul;1861(7):1661-1675
pubmed: 28411077
Int J Cancer. 2014 Apr 15;134(8):1776-84
pubmed: 24122582
Curr Genomics. 2007 Jun;8(4):229-33
pubmed: 18645597
Cell Biochem Funct. 2016 Apr;34(3):142-8
pubmed: 26916216
Genes Cancer. 2013 Jan;4(1-2):61-9
pubmed: 23946872
Neoplasma. 2016;63(6):952-960
pubmed: 27596295
Oncol Lett. 2017 Sep;14(3):3817-3824
pubmed: 28927152
Int J Mol Med. 2014 Apr;33(4):879-86
pubmed: 24424572
Investig Clin Urol. 2016 Jun;57 Suppl 1:S60-76
pubmed: 27326409
Ther Adv Urol. 2012 Feb;4(1):13-32
pubmed: 22295042
Int J Cancer. 2011 Mar 15;128(6):1327-34
pubmed: 20473948
PLoS One. 2012;7(6):e39309
pubmed: 22745731
Curr Pharm Des. 2014;20(42):6565-74
pubmed: 25341933
Cell Tissue Res. 2013 Nov;354(2):533-41
pubmed: 24036903
Mod Pathol. 2009 Jun;22 Suppl 2:S60-9
pubmed: 19494854
Scand J Urol. 2013 Oct;47(5):423-32
pubmed: 23206218
Mol Cancer. 2015 Nov 14;14:194
pubmed: 26576778
Eur Urol Focus. 2019 May;5(3):457-466
pubmed: 29366854
Cell Death Dis. 2015 Oct 15;6:e1907
pubmed: 26469956
J Hematol Oncol. 2015 Oct 24;8:119
pubmed: 26497743
Oncol Rep. 2012 Jun;27(6):1967-75
pubmed: 22407299
DNA Cell Biol. 2015 Oct;34(10):626-32
pubmed: 26230405
Oncotarget. 2015 Dec 8;6(39):42258-75
pubmed: 26517683
Cancers (Basel). 2018 Apr 01;10(4):null
pubmed: 29614760
Onco Targets Ther. 2016 Apr 05;9:2019-25
pubmed: 27103828
Genes Dev. 2009 Mar 15;23(6):675-80
pubmed: 19261747
Gut. 2016 Jun;65(6):977-989
pubmed: 25804630
Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36
pubmed: 19779035
PLoS One. 2016 Jul 20;11(7):e0159115
pubmed: 27438131
Front Genet. 2018 Sep 28;9:422
pubmed: 30323832
Cancer Cell Int. 2014 Jul 19;14:70
pubmed: 25414595
Int J Mol Cell Med. 2015 Winter;4(1):32-9
pubmed: 25815280
Oncotarget. 2018 Feb 07;9(45):27656-27666
pubmed: 29963227
Cancer Sci. 2016 Sep;107(9):1233-42
pubmed: 27355528
Urol J. 2015 Feb 22;12(1):2010-3
pubmed: 25703910